Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Recruiting · NCT06138587 · Registry updated 2026-06-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, myeloproliferative neoplasm, neoplasm | Recruiting | Phase 1 | 2026-06-17 | NCT06138587 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 60 |
| Dana-Farber Cancer Institute | Boston | United States | 68 |